Ask anyone what a blood bank gives patients and you’ll hear “blood”. Ask a transfusion doctor and you’ll hear a vocabulary most people never meet: packed red cells, fresh frozen plasma, platelets, and then, in quieter corners of the ward, two products with odd names and outsized importance. Cryoprecipitate and albumin are the lesser-known gifts of donation, and both begin exactly where every blood product begins: with a donor.
Cryoprecipitate: a clotting kit in a tiny bag
Cryoprecipitate (“cryo” to everyone who works with it) is born from patience and cold. Take a bag of frozen plasma and thaw it slowly in a refrigerator. As it melts, a small amount of material stays behind, clinging to the bag as a cold-insoluble residue. That residue is cryoprecipitate, and it happens to be a concentrated packet of the proteins blood uses to build clots: fibrinogen above all, along with factor VIII, von Willebrand factor and factor XIII.
What is it for? Serious bleeding. In massive haemorrhage (road accidents, childbirth emergencies, cardiac surgery) the body burns through its fibrinogen, and clotting stalls. Cryo replenishes fibrinogen in a small volume, which matters when a patient is being flooded with fluids. In some settings it also serves patients with bleeding disorders where modern factor concentrates are unavailable. Historically, cryoprecipitate was a lifeline for people with haemophilia before purified factor products existed; it remains a workhorse wherever bleeding runs ahead of the clotting system.
Albumin: the pressure keeper
Albumin is a different kind of gift. It is the most abundant protein in plasma, and its core job is unglamorous but vital: it keeps fluid inside the blood vessels. Water follows albumin, so albumin maintains the osmotic pressure that stops blood volume from leaking into tissues.
Medicine calls on albumin when that pressure fails. Major burns weep plasma through damaged skin, and albumin helps hold volume in. Advanced liver disease makes albumin, so patients with cirrhosis may need infusions during complications or before large fluid removals. It supports critically ill patients whose vessels are leaking. One important manufacturing note: therapeutic albumin is produced by fractionating large pooled batches of plasma, and the process includes heat treatment, a legacy of hard lessons about virus transmission that made the product safer.
Both roads lead back to a donor
Here is the part worth sitting with. Cryoprecipitate comes from single units of donated whole blood, separated in the local blood bank. Albumin comes from pools of thousands of plasma donations, fractionated at industrial scale. Neither is synthesised from chemicals in a factory. There is no machine that makes fibrinogen, no reactor that produces albumin. Every dose of these products, anywhere in the world, is the processed generosity of people who rolled up a sleeve, in albumin’s case, quite possibly thousands of people the patient will never know.
Why the lesser-known products matter
Component separation is often described as efficiency, and it is: one donation, several patients. But the deeper point is medical precision. A bleeding mother does not need a general top-up; she needs fibrinogen, now. A burns patient does not need cells; he needs volume held in his vessels. Cryo and albumin let doctors give exactly what’s missing instead of approximating with whole blood, which is why transfusion has shifted from “give blood” to “give the right part of blood”.
And that is why the register matters more than it seems. A rare fibrinogen crisis at 2 a.m. is solved by cryo made hours or days earlier from someone’s routine donation. The unremarkable Saturday-morning donor, who felt slightly light-headed and had a biscuit afterwards, is part of that story. You can be too: register as a donor.
To see how a single donation becomes products like these, follow the journey of a blood bag, browse all the components and what they treat, or start with what blood is made of.